Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review

  • ID: 1292070
  • SWOT Analysis
  • 66 pages
  • GlobalData
  • Grifols, S.A.
1 of 5

FEATURED COMPANIES

  • AB-Biotics SA
  • Abeona Therapeutics Inc
  • CSL Ltd
  • HemaCare Corp
  • Oryzon Genomics SA
  • MORE
Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Grifols SA (Grifols) focuses at improving the health and well-being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. The company specializes in the production of plasma-derived medicines and has plasma donation centers across the US. Grifols provides a wide range of transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. The company offers its products to hospitals, pharmacies and healthcare professionals. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.

Grifols SA Key Recent Developments

May 10, 2018: Grifols reaches an agreement with Boya Bio-Pharmaceutical to open plasma collection centers in China
May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales
Apr 17, 2018: Grifols donates over 25 million international units of blood clotting factor in 2017
Mar 05, 2018: Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
Dec 04, 2017: Grifols Misterium Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB-Biotics SA
  • Abeona Therapeutics Inc
  • CSL Ltd
  • HemaCare Corp
  • Oryzon Genomics SA
  • MORE
Section 1 - About the Company
  • Grifols SA - Key Facts
  • Grifols SA - Key Employees
  • Grifols SA - Key Employee Biographies
  • Grifols SA - Major Products and Services
  • Grifols SA - History
  • Grifols SA - Company Statement
  • Grifols SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Grifols SA - Business Description
  • Business Segment: Bio Supplies
  • Overview
  • Performance
  • Business Segment: Bioscience
  • Overview
  • Performance
  • Key Stats
  • Business Segment: Diagnostic
  • Overview
  • Performance
  • Business Segment: Hospital
  • Overview
  • Performance
  • Business Segment: Other Segment
  • Overview
  • Performance
  • Geographical Segment: European Union
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: USA and Canada
  • Performance
  • R&D Overview
  • Grifols SA - Corporate Strategy
  • Grifols SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Grifols SA - Strengths
  • Grifols SA - Weaknesses
  • Grifols SA - Opportunities
  • Grifols SA - Threats
  • Grifols SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Grifols SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 10, 2018: Grifols reaches an agreement with Boya Bio-Pharmaceutical to open plasma collection centers in China
  • May 03, 2018: Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales
  • Apr 17, 2018: Grifols donates over 25 million international units of blood clotting factor in 2017
  • Mar 05, 2018: Grifols Announces New Agreement with Henry Schein to Distribute Normal Saline Solution in the U.S.
  • Dec 04, 2017: Grifols Misterium Cleanroom Solutions Expands to Include Revolutionary Decontamination Air and Surface Disinfection Systems for Pharmaceutical Preparation
  • Nov 22, 2017: Grifols inaugurates a new plant of the Diagnostic Division in Brazil to manufacture storage and collection bags for blood components
  • Nov 02, 2017: Grifols increases its revenues by 10% to Euros 3,250 million and grows net profit by 6.3% to reach Euros 432 million
  • Sep 22, 2017: An ISCIII researcher awarded for her work on Alpha-1 Antitrypsin Deficiency (DAAT)
  • Aug 22, 2017: Grifols Phocus Rx Pharmacy Workflow Management Solution Now Integrates With Top Hospital Information Systems via HL7 Interfaces
  • Jul 28, 2017: Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Grifols SA, Key Facts
  • Grifols SA, Key Employees
  • Grifols SA, Key Employee Biographies
  • Grifols SA, Major Products and Services
  • Grifols SA, History
  • Grifols SA, Other Locations
  • Grifols SA, Subsidiaries
  • Grifols SA, Key Competitors
  • Grifols SA, Ratios based on current share price
  • Grifols SA, Annual Ratios
  • Grifols SA, Annual Ratios
  • Grifols SA, Annual Ratios
  • Grifols SA, Interim Ratios
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Grifols SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Grifols SA, Performance Chart (2013 - 2017)
  • Grifols SA, Ratio Charts
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB-Biotics SA
  • CSL Ltd
  • HemaCare Corp
  • Oryzon Genomics SA
  • Abeona Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll